DGIdb - DOCETAXEL Drug Record

DOCETAXEL chembl:CHEMBL92 ApprovedAntineoplasticImmunotherapy

Alternate Names:

RP-56976
TAXOTERE
DOCETAXEL, ANHYDROUS
N-DEBENZOYL-N-(TERT-BUTOXYCARBONYL)-10-DEACETYLTAXOL
TXL
DOCETAXEL
DOCECAD®
N-DEBENZOYL-N-(TERT-BUTOXYCARBONYL)-10-DEACETYLPACLITAXEL
EMDOC
DOCETAXEL ANHYDROUS
TAXOTERE®
pubchem.compound:148124
drugbank:01248
chemidplus:114977-28-5
chembl:CHEMBL92
rxcui:1299922

Drug Info:

FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antineoplastic agent
Year of Approval	1996
Drug Class	antineoplastic agents
Pharmaceutical Developer	BIND Biosciences
Source Reported Drug Name(s)	BIND-014/PSMA-targeted docetaxel nanoparticle
Drug Class	Folate Inhibitor

(10 More Sources)

Publications:

He et al., 2013, Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma., Cancer Discov
Chew SC et al., 2014, Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXRα and HNF4α) on docetaxel disposition in Chinese nasopharyngeal cancer patients., Eur J Clin Pharmacol
Ikezoe et al., 2004, HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo., Cancer Res.
Coté D et al., 2018, Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)., PLoS One
Voon PJ et al., 2013, Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients., Br J Clin Pharmacol
Rosell et al., 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial., Lancet Oncol.
Zhou et al., 2011, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study., Lancet Oncol.
Deeken JF et al., 2010, A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform., Pharmacogenomics J
Sun et al., 2009, Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients., Lung Cancer
Edvardsen H et al., 2010, SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance., Pharmacogenomics J
Yang et al., 2011, p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer., Int. J. Oncol.
Chen et al., 2012, A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response., Nature
Lee et al., 2016, Growth Arrest-Specific 6 (GAS6) Promotes Prostate Cancer Survival by G1 Arrest/S Phase Delay and Inhibition of Apoptosis During Chemotherapy in Bone Marrow., J. Cell. Biochem.
Oshiro C et al., 2009, Taxane pathway., Pharmacogenet Genomics
Hohla et al., 2006, Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel., Proc. Natl. Acad. Sci. U.S.A.
Li Y et al., 2011, Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy., Clin Cancer Res
Dong et al., 2014, Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression., PLoS ONE
Younis IR et al., 2014, Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer., Cancer Chemother Pharmacol
Wacheck et al., 2006, Mcl-1 is a relevant molecular target for antisense oligonucleotide strategies in gastric cancer cells., Cancer Biol. Ther.
McWhinney-Glass S et al., 2013, Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity., Clin Cancer Res
Petrylak, 2005, Chemotherapy for androgen-independent prostate cancer., World J Urol
Marshall et al., 2004, A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors., Ann. Oncol.
Inoue et al., 2005, Bcl-2 overexpression enhances in vitro sensitivity against docetaxel in non-small cell lung cancer., Oncol. Rep.
Miyoshi et al., 2005, [Treatment of androgen-independent hormone refractory prostate cancer using docetaxel]., Nippon Rinsho
Gligorov et al., 2004, Preclinical pharmacology of the taxanes: implications of the differences., Oncologist
Magi-Galluzzi et al., 2007, Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study., Cancer
Baselga et al., 2012, Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer., N. Engl. J. Med.
Swain et al., 2015, Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer., N. Engl. J. Med.
Mackey et al., 2015, Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer., J. Clin. Oncol.
Blumenthal et al., 2013, First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer., Clin. Cancer Res.
Martin et al., 2016, Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study., Ann. Oncol.
Takahashi H et al., 2019, Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma., J Clin Oncol
Le Morvan V et al., 2015, Identification of SNPs associated with response of breast cancer patients to neoadjuvant chemotherapy in the EORTC-10994 randomized phase III trial., Pharmacogenomics J
Smith et al., 2005, Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel., Cancer Biol. Ther.
Reimer T et al., 2016, SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study., BMC Cancer
Marth et al., 1997, Paclitaxel- and docetaxel-dependent activation of CA-125 expression in human ovarian carcinoma cells., Cancer Res.
Massacesi et al., Serum tumor markers may precede instrumental response to chemotherapy in patients with metastatic cancer., Int. J. Biol. Markers
Tran et al., 2006, Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms., Clin. Pharmacol. Ther.
Vidal et al., 2015, A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer., Cancer Cell
Matesanz et al., 2008, Optimization of taxane binding to microtubules: binding affinity dissection and incremental construction of a high-affinity analog of paclitaxel., Chem. Biol.
Snyder et al., 2001, The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density., Proc. Natl. Acad. Sci. U.S.A.
Belani et al., 2004, Development of docetaxel in advanced non-small-cell lung cancer., Lung Cancer
Bosó V et al., 2014, SNPs and taxane toxicity in breast cancer patients., Pharmacogenomics
Kong SY et al., 2009, Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer., Pharmacogenomics
Kiyotani K et al., 2008, Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia., Cancer Sci
De Mattia E et al., 2016, Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine., Pharmacogenomics
Springate et al., 2005, Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models., Cancer Chemother. Pharmacol.
Weitzman et al., 2000, Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer., J. Urol.
Okamura et al., 2000, NADPH/quinone oxidoreductase is a priority target of glioblastoma chemotherapy., Int. J. Oncol.
Takemura et al., 2005, Enhanced Bax in oral SCC in relation to antitumor effects of chemotherapy., J. Oral Pathol. Med.
Hein A et al., 2015, Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study., Int J Cancer
Derosa L et al., 2014, Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients., Cancer
Koutras AK et al., 2014, Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel., Pharmacogenomics J
Dong N et al., 2012, Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine., J Cancer Res Clin Oncol
Qian J et al., 2012, Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment., Chest
Jänne et al., 2015, Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer., Br. J. Cancer
Gandara et al., 2017, A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer., J Thorac Oncol
Jänne et al., 2013, Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study., Lancet Oncol.
Jänne et al., 2017, Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial., JAMA
Cui et al., 2015, Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer., Clin. Cancer Res.
Engleson et al., 2006, Midline carcinoma with t(15;19) and BRD4-NUT fusion oncogene in a 30-year-old female with response to docetaxel and radiotherapy., BMC Cancer
Lewis LD et al., 2013, The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance)., Pharmacogenet Genomics
Grünewald S et al., 2019, Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models., Int J Cancer

DOCETAXEL PRDX4

Interaction Score: 1.61

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20157331

Sources:
PharmGKB
DOCETAXEL ORM2

Interaction Score: 1.61

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24619498

Sources:
PharmGKB
DOCETAXEL SNORD68

Interaction Score: 0.81

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20038957

Sources:
PharmGKB
DOCETAXEL XRCC4

Interaction Score: 0.81

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20157331

Sources:
PharmGKB
DOCETAXEL SULT1C4

Interaction Score: 0.81

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20038957

Sources:
PharmGKB
DOCETAXEL CHST3

Interaction Score: 0.81

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20038957

Sources:
PharmGKB
DOCETAXEL RPL13

Interaction Score: 0.81

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20038957

Sources:
PharmGKB
DOCETAXEL VAC14

Interaction Score: 0.81

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DOCETAXEL GAS6

Interaction Score: 0.81

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27153245

Sources:
CIViC
DOCETAXEL SPG7

Interaction Score: 0.81

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20038957

Sources:
PharmGKB
DOCETAXEL CYP4B1

Interaction Score: 0.81

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20038957

Sources:
PharmGKB
DOCETAXEL ABCC6

Interaction Score: 0.54

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20038957

Sources:
PharmGKB
DOCETAXEL RNF8

Interaction Score: 0.54

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30071039

Sources:
PharmGKB
DOCETAXEL SOX10

Interaction Score: 0.4

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23963862

Sources:
PharmGKB
DOCETAXEL TLE3

Interaction Score: 0.4

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers
DOCETAXEL SLC10A2

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20038957

Sources:
PharmGKB
DOCETAXEL BARD1

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30071039

Sources:
PharmGKB
DOCETAXEL MDM4

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24958282

Sources:
PharmGKB
DOCETAXEL MUC16

Interaction Score: 0.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9288793 14756546

Sources:
NCI
DOCETAXEL ATP7A

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20038957

Sources:
PharmGKB
DOCETAXEL ACSS2

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21636554

Sources:
PharmGKB
DOCETAXEL PGP

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers
DOCETAXEL EPHX1

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20157331

Sources:
PharmGKB
DOCETAXEL PPCDC

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DOCETAXEL MAP3K1

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21636554

Sources:
PharmGKB
DOCETAXEL FBXW7

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type resistant

Approval Status Preclinical

PMIDs:
23274910

Sources:
JAX-CKB
DOCETAXEL NR1I3

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27561454 24193570

Sources:
PharmGKB
DOCETAXEL BCL2

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name BIND-014

Novel drug target Established target

Trial Name Docetaxel

PMIDs:
23963862 15685445 15277270 15643508 15714982 15161985 17674353

Sources:
TdgClinicalTrial PharmGKB
DOCETAXEL ERCC2

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25495407

Sources:
PharmGKB
DOCETAXEL XRCC1

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19157633

Sources:
CIViC
DOCETAXEL AKR1C3

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23116553

Sources:
PharmGKB
DOCETAXEL FOLH1

Interaction Score: 0.15

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Reported Cancer Type Prostate

PMIDs:
None found

Sources:
ClearityFoundationClinicalTrial CancerCommons
DOCETAXEL KLK3

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15864591 10687988

Sources:
NCI
DOCETAXEL IGF2

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25670080

Sources:
CIViC
DOCETAXEL RRM1

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24647522

Sources:
CIViC
DOCETAXEL HNF4A

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24193570

Sources:
PharmGKB
DOCETAXEL STK11

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

Alteration STK11:.;KRAS:.

Alteration STK11:del;KRAS:.

Drug family MEK inhibitor;Chemotherapy

PMIDs:
22425996

Sources:
CGI CIViC
DOCETAXEL SLCO1B3

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21151855 18294295

Sources:
PharmGKB
DOCETAXEL BRD4

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16542442

Sources:
NCI
DOCETAXEL NOTCH1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy PF-03084014 + Docetaxel

Indication/Tumor Type prostate cancer

Response Type predicted – sensitive

PMIDs:
26202948

Sources:
JAX-CKB
DOCETAXEL ERCC1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25495407

Sources:
PharmGKB
DOCETAXEL TUBB1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name ANX-514, lyophilized docetaxel

Novel drug target Established target

Trial Name ATI-1123

PMIDs:
15161985 18559268 11309480 15698529

Sources:
TdgClinicalTrial TEND
DOCETAXEL NAT2

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20038957

Sources:
PharmGKB
DOCETAXEL VEGFA

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26100253 25111199 24061601

Sources:
PharmGKB
DOCETAXEL CASP7

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22441531

Sources:
PharmGKB
DOCETAXEL GSTM1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16765145

Sources:
NCI
DOCETAXEL CYP1A1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22426923

Sources:
PharmGKB
DOCETAXEL CYP2A6

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19604090

Sources:
PharmGKB
DOCETAXEL RAF1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21636554

Sources:
PharmGKB
DOCETAXEL ABCC2

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23188068 21151855 18294295

Sources:
PharmGKB
DOCETAXEL SLCO1B1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16210916 27234217

Sources:
NCI PharmGKB
DOCETAXEL CYP1B1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21151855

Sources:
PharmGKB
DOCETAXEL TUB

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
DOCETAXEL ERBB3

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30071039

Sources:
PharmGKB
DOCETAXEL ERBB2

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Docetaxel + T-DM1 + Pertuzumab

Indication/Tumor Type Her2-receptor positive breast cancer

Response Type sensitive

PMIDs:
22149875 25693012 30071039 25185099 23801166 27052654 30452336

Sources:
JAX-CKB CIViC PharmGKB
DOCETAXEL HRAS

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16983095

Sources:
NCI
DOCETAXEL KRAS

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Selumetinib + Docetaxel

Indication/Tumor Type non-small cell lung carcinoma

Response Type no benefit

PMIDs:
26125448 27876675 23200175 28492898

Sources:
JAX-CKB CGI CIViC
DOCETAXEL BAX

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15641988

Sources:
NCI
DOCETAXEL GSTP1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10639573

Sources:
NCI
DOCETAXEL MCL1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16969094

Sources:
NCI
DOCETAXEL ABCC1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21151855

Sources:
PharmGKB
DOCETAXEL PGR

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA
DOCETAXEL ABCG2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21151855

Sources:
PharmGKB
DOCETAXEL BIRC5

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers
DOCETAXEL CYP19A1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DOCETAXEL RXRA

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24193570

Sources:
PharmGKB
DOCETAXEL NR1I2

Interaction Score: 0.02

Interaction Types & Directionality:

binder

Interaction Info:

PMIDs:
24193570 15492266

Sources:
PharmGKB
DOCETAXEL TUBB3

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers
DOCETAXEL FGFR1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30807645

Sources:
CIViC
DOCETAXEL CYP3A5

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21151855

Sources:
PharmGKB
DOCETAXEL TUBB

Interaction Score: 0.02

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True

PMIDs:
None found

Sources:
GuideToPharmacology
DOCETAXEL EGFR

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22285168 21783417

Sources:
PharmGKB
DOCETAXEL OPRM1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23963862

Sources:
PharmGKB
DOCETAXEL PPARD

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20038957

Sources:
PharmGKB
DOCETAXEL ESR2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DOCETAXEL PIK3CA

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20157331

Sources:
PharmGKB
DOCETAXEL TP53

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Phase I

Response Type sensitive

PMIDs:
21399868 22425996

Sources:
JAX-CKB CIViC
DOCETAXEL ESR1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA
DOCETAXEL ABCB1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21151855

Sources:
PharmGKB

CancerCommons: DOCETAXEL
- Version: 25-July-2013
Alternate Names:

Docetaxel Drug Development Name

Docetaxel Drug Trade Name

Drug Info:

Drug Class Folate Inhibitor

Source Reported Drug Name(s) BIND-014/PSMA-targeted docetaxel nanoparticle

Pharmaceutical Developer BIND Biosciences

Publications:
TEND: DOCETAXEL
- Version: 01-August-2011
Alternate Names:

DOCETAXEL Primary Drug Name

Drug Info:

Drug Class antineoplastic agents

Year of Approval 1996

Publications:
TdgClinicalTrial: DOCETAXEL
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: DOCETAXEL

Version: 14-September-2017

Alternate Names:

C1526 NCI drug code

Drug Info:

Publications:

Tran et al., 2006, Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms., Clin. Pharmacol. Ther.

Takemura et al., 2005, Enhanced Bax in oral SCC in relation to antitumor effects of chemotherapy., J. Oral Pathol. Med.

Engleson et al., 2006, Midline carcinoma with t(15;19) and BRD4-NUT fusion oncogene in a 30-year-old female with response to docetaxel and radiotherapy., BMC Cancer

JAX-CKB: Docetaxel

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

He et al., 2013, Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma., Cancer Discov

Blumenthal et al., 2013, First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer., Clin. Cancer Res.

Martin et al., 2016, Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study., Ann. Oncol.

PharmGKB: docetaxel

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Chew SC et al., 2014, Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXRα and HNF4α) on docetaxel disposition in Chinese nasopharyngeal cancer patients., Eur J Clin Pharmacol

Voon PJ et al., 2013, Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients., Br J Clin Pharmacol

Edvardsen H et al., 2010, SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance., Pharmacogenomics J

CIViC: DOCETAXEL

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Jänne et al., 2013, Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study., Lancet Oncol.

Gandara et al., 2017, A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer., J Thorac Oncol

Jänne et al., 2015, Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer., Br. J. Cancer

TTD: Docetaxel
- Version: 2020.06.01
Alternate Names:

D0O5WP TTD Drug ID

Drug Info:

Publications:
GuideToPharmacology: 178103415
- Version: 29-September-2020
Alternate Names:

DOCETAXEL GuideToPharmacology Ligand Name

Drug Info:

Publications:
ClearityFoundationClinicalTrial: DOCETAXEL
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL92
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
CGI: Docetaxel
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:
ClearityFoundationBiomarkers: DOCETAXEL
- Version: 26-July-2013
Alternate Names:

Drug Info:

Publications:
FDA: Docetaxel
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Indication/Tumor Type	Advanced Solid Tumor
Response Type	resistant
Approval Status	Preclinical

Trial Name	BIND-014
Novel drug target	Established target
Trial Name	Docetaxel

Alteration	STK11:.;KRAS:.
Alteration	STK11:del;KRAS:.
Drug family	MEK inhibitor;Chemotherapy

combination therapy	PF-03084014 + Docetaxel
Indication/Tumor Type	prostate cancer
Response Type	predicted – sensitive

Trial Name	ANX-514, lyophilized docetaxel
Novel drug target	Established target
Trial Name	ATI-1123

combination therapy	Docetaxel + T-DM1 + Pertuzumab
Indication/Tumor Type	Her2-receptor positive breast cancer
Response Type	sensitive

combination therapy	Selumetinib + Docetaxel
Indication/Tumor Type	non-small cell lung carcinoma
Response Type	no benefit

Specific Action of the Ligand	Inhibition
Endogenous Drug?	False
Direct Interaction?	True

Evidence Type	Actionable
Approval Status	Phase I
Response Type	sensitive

DOCETAXEL Drug Record

DOCETAXEL chembl:CHEMBL92 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20157331

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24619498

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20038957

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20157331

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20038957

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20038957

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20038957

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27153245

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20038957

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20038957

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20038957

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 30071039

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23963862

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: ClearityFoundationBiomarkers

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20038957

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 30071039

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24958282

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9288793 14756546

Interaction Types & Directionality:

n/a

PMIDs:
20157331

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24619498

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20038957

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20157331

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20038957

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20038957

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20038957

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27153245

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
20038957

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20038957

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20038957

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
30071039

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23963862

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers

Interaction Types & Directionality:

n/a

PMIDs:
20038957

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
30071039

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24958282

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
9288793 14756546

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
20038957

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
21636554

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers

Interaction Types & Directionality:

n/a

PMIDs:
20157331

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
21636554

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type resistant

Approval Status Preclinical

PMIDs:
23274910

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a